key: cord-0790432-zncgyui3
authors: Younes, Salma; Younes, Nadin; Shurrab, Farah; Nasrallah, Gheyath K.
title: Severe acute respiratory syndrome coronavirus‐2 natural animal reservoirs and experimental models: systematic review
date: 2020-11-18
journal: Rev Med Virol
DOI: 10.1002/rmv.2196
sha: fdb9c7002286c53b7624efb0187fd4cc90581bd2
doc_id: 790432
cord_uid: zncgyui3

The current severe acute respiratory syndrome coronavirus‐2 (SARS‐CoV‐2) outbreak has been rapidly spreading worldwide, causing serious global concern. The role that animal hosts play in disease transmission is still understudied and researchers wish to find suitable animal models for fundamental research and drug discovery. In this systematic review, we aimed to compile and discuss all articles that describe experimental or natural infections with SARS‐CoV‐2, from the initial discovery of the virus in December 2019 through to October 2020. We systematically searched four databases (Scopus, PubMed, Science Direct and Web of Science). The following data were extracted from the included studies: type of infection (natural or experimental), age, sample numbers, dose, route of inoculation, viral replication, detection method, clinical symptoms and transmission. Fifty‐four studies were included, of which 34 were conducted on animal reservoirs (naturally or experimentally infected), and 20 involved models for testing vaccines and therapeutics. Our search revealed that Rousettus aegyptiacus (fruit bats), pangolins, felines, mink, ferrets and rabbits were all susceptible to SARS‐CoV‐2, while dogs were weakly susceptible and pigs, poultry, and tree shrews were not. In addition, virus replication in mice, mink, hamsters and ferrets resembled subclinical human infection, so these animals might serve as useful models for future studies to evaluate vaccines or antiviral agents and to study host‐pathogen interactions. Our review comprehensively summarized current evidence on SARS‐CoV‐2 infection in animals and their usefulness as models for studying vaccines and antiviral drugs. Our findings may direct future studies for vaccine development, antiviral drugs and therapeutic agents to manage SARS‐CoV‐2‐caused diseases.

The outbreak of coronavirus disease 2019 caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has triggered a serious global public health problem and is spreading in almost all countries around the globe with 45,797,600 confirmed cases and 1,191,670 mortalities, as of 30 October 2020. 1 The current outbreak of SARS-CoV-2 is the third outbreak of animal coronavirus transmission to humans in the past 2 decades. SARS-CoV-2 belongs to the coronaviruses (CoVs), a genus in the Coronaviridae family. Most known CoVs infect animals, are associated with self-limiting diseases and have a narrow host range. 2 However, some zoonotic CoVs have a high capability to mutate, which enables the virus to cross the species barrier to infect humans, such as SARS-CoV, middle east respiratory syndrome coronavirus (MERS-CoV), and SARS-CoV-2 zoonotic viruses, which have caused severe acute respiratory diseases in humans. [3] [4] [5] These zoonotic CoVs have claimed thousands of lives in the last 2 decades. 4 Fortunately, compared to SARS-CoV and MERS-CoV, SARS-CoV-2 is less pathogenic; however, the concern lies in the fact that it is highly infectious and transmissible. Moreover, asymptomatic Covid-19 patients have been shown to contribute to the transmission of the infection around the world. 6, 7 Recent reports and studies of SARS-CoV-2 in animals have caused unnecessary fear and panic among the population, which have adversely affected the wellbeing and health of animals. Most importantly, it is unethical to cull any animals (wild or domestic) by declaring they are 'potential' reservoir hosts without any conclusive evidence that they can transmit SARS-CoV-2 to humans. Furthermore, finding the best animal models that mimic human Covid-19 infection is vital for scientists to understand the pathogenesis of SARS-CoV-2 infection. In addition, animal models are critical for testing potential vaccines and therapeutic agents. 8 A suitable animal model is one that can mimic human disease in terms of viral load, morbidity, clinical signs, and the immune response. Due to the urgency and demand in the current crisis, there is a pressing need to search for a good animal model to control the SARS-CoV-2 outbreak. 9 In this systematic review, we provide a summary of the current evidence on natural and experimental infections of SARS-CoV-2 in animals. We compare different animals for their susceptibility, clinical signs, transmission dynamics, and immune response. We also discuss the ability of these animals to mimic Covid-19 pathogenesis in humans, as well as their usefulness as ideal models for preclinical testing of vaccine candidates and therapeutic agents.

This systematic review was performed according to the preferred reporting items for systematic reviews and meta-analyses (PRISMA) statement. 10 

We included published articles that reported infection in domestic or wild animals with serological or molecular confirmation of SARS-CoV-2. Inclusion criteria included: (1) investigation of the management of SARS-CoV-2 and (2) natural or experimentally induced SARS-CoV-2-infected animal species. Exclusion criteria included (1) infection not clearly defined as SARS-CoV-2, (2) non-animal models,

(3) reviews, meta-analyses, book reviews, letters, abstracts and cases and (4) non-English reports. 

Four reviewers participated in screening and study selection, of which, three reviewers individually reviewed the identified studies (Salma Younes, Nadin Younes and Farah Shurrab), and a fourth reviewer (Gheyath K. Nasrallah) resolved any discrepancies. All studies retrieved from our initial search strategy were imported to Endnote X9 library, after which, duplicates were removed. Figure 1 illustrates the search strategy. Studies were screened in two stages. The first stage of screening involved screening of titles, abstracts, and keywords. The 

Two reviewers (Salma Younes and Nadin Younes) extracted the following data from each included study: animal used, age, number of animals used, type of infection (natural/experimental), inoculation dose, route of challenge, sample, method of detection, immune response, disease and pathology (symptoms), and the possibility of animal-animal transmission (Table S1 ). For vaccine and therapeutic studies on animal models infected with SARS-CoV-2; the following information were extracted and recorded: animal model, age, number of animals used, inoculation dose, route of challenge, vaccine/antiviral agent, dose, route of inoculation, sample type, method of detection, disease and pathology (symptoms), and the main outcomes of each study (Table S2 ). The information collected was reviewed independently by all authors to ensure accurate data collection.

We identified 19,012 articles, of which 14,068 remained after the removal of duplicates. Thirteen thousand eight hundred eighty-one irrelevant articles were excluded during the initial stage of screening and 148 articles were excluded during the second stage ( Figure 1 ).

The majority of the excluded studies were mainly in vivo human studies with no data on experimental or natural animal species. A total of 54 articles were included in the systematic review.

The studies collected using the systematic search used various animal species infected with SARS-CoV-2 experimentally or naturally. Most of the studies were conducted on mice (37%) and NHPs (30%), fewer studies were conducted on felines, poultry, dogs, ferrets, fruit bats, minks, hamsters, pigs, rabbits, and tree shrews as shown in Figure 2 .

A consolidative summary of the data gathered from all studies F I G U R E 1 Prisma flow diagram of the systematic review study selection process. The search strategy yielded 19,012 studies. A total of 54 studies were included in the systematic review. SARS-CoV-2, severe acute respiratory syndrome coronavirus-2 YOUNES ET AL. included in this systematic review is given in Table 1 . The data collected from each study included in this systematic review are presented in Table S1 and Table S2 .

There is a strong evidence that SARS-CoV-2 virus originated in bats 64 ; however, the intermediate animal host is still unknown ( Figure 3) . Several studies showed that pangolins, snakes, turtles, and mink are all possible intermediate hosts, however, further investigations are needed. [66] [67] [68] It is worth mentioning that recent findings that analyse the probable animal reservoir to Covid-19

suggest the snake as a reservoir, based on relative synonymous codon usage bias. 67 However, the missing link or intermediate link for animal to human transmission of SARS-CoV-2 from a recent study suggests the DNA and protein sequence of Malayan pangolins. 69 Studies included in our systematic search revealed low SARS-CoV-2 replication in pigs, dogs, chickens, ducks, rabbits and treeshrews ( Table 1, Table S1 and Figure 4 ). However, Rousettus aegyptiacus (fruit bats), pangolins, felines, mink, ferrets and rabbits were all susceptible to SARS-CoV-2 ( Table 1, Table S1 and Figure 4 ).

Additionally, tigers, ferrets, mink, macaques, lions, hamsters and cats are susceptible to animal-to-animal transmission through the airborne route (Table 1 and Table S1 ). Moreover, susceptible animals are capable of producing neutralizing antibodies (NAbs) that can offer protection against reinfection (Table S1) ; however, it remains unclear how long protection will last.

SARS-CoV-2 was first identified in Wuhan city in China in hospitalized patients who previously visited the Huanan wet seafood market where various animals including chickens, pigs, pangolins, bats, snakes, frogs, rabbits, and marmots are sold for human consumption, proposing a suitable environment for zoonotic infection spill-over to humans. 67, [70] [71] [72] [73] Scientists believe that these traditional Chinese practices might be responsible for the SARS-CoV-2 pandemic in humans and that the recurrent interactions between humans and animals without proper biosafety measures present a substantial risk for the occurrence of zoonotic diseases. 74 Zoonotic CoVs have crossed the species barrier twice in the past 2 decades (SARS-CoV; 2002 and MERS-CoV; 2012). Thus, scientists F I G U R E 2 Characteristics of the included studies. Articles obtained from the systematic search were categorized based on the animal used in each study. Most of the studies were conducted on mice and NHPs. Fewer studies were conducted on felines, poultry, dogs, ferrets, fruit bats, minks, hamsters, pigs, rabbits, and tree shrews. Some studies included more than one animal; NHPs, non-human primates have speculated that SARS-CoV-2 resulted from a zoonotic spillover event as well. Zoonotic CoVs need to propagate in their zoonotic reservoirs, and then, seek the chances to spillover via intermediate hosts into susceptible human targets, where they can maintain humanto-human transmission. Bats have been revealed as the natural hosts for several human CoVs, including HCoV-NL63, HCoV-229E, SARS-CoV, and MERS-CoV. 75, 76 Genome sequence analysis confirmed that SARS-CoV-2 is 96% identical to the bat CoV RaTG13 at the wholegenomic level, 77 and hence bats are believed to be the primary source of origin for the novel SARS-CoV-2. However, the intermediate host that is yet to be elucidated. 11, 67, 70, 72, 78 Researchers proposed two hypotheses for the emergence of SARS-CoV-2: (1) Natural selection may have occurred in an animal host before transmission to mankind; and (2) natural selection of viruses may have occurred in humans after zoonotic transmission. 79 In this regard, studies involving the use of animal models or cell culture are in need to help clarify these two scenarios. 79 

Infections with SARS-CoV-2 have been documented in various animal species naturally or by experimental infection (Table 1 and   Table S1 ). Our systematic search revealed that R. aegyptiacus fruit bats, pangolins, felines, minks, NHPs, hamsters, ferrets and rabbits are all susceptible to SARS-CoV-2, dogs are weakly susceptible, whereas pigs, poultry, and tree shrews are not susceptible to SARS-CoV-2 infection (Table 1 and Table S1 ).

Bats SARS-CoV and MERS-CoV originated in bats and were capable of infecting humans. 80, 81 Bats are known to be the ideal hosts for pathogenic CoVs, as viruses remain persistent in asymptomatic T A B L E 1 Summary of findings of SARS-CoV-2 infection in animals bats. 82 Accordingly, researchers predicted the role of bats as the origin of the current SARS-CoV-2 outbreak. 68, [82] [83] [84] Several studies showed that SARS-CoV-2 is virtually identical to the bat CoV on a genomic level, hence it is assumed that bats are the primary source of the SARS-CoV-2 spillover. 83, 85 Experimental studies revealed that R. aegyptiacus fruit bats are susceptible to SARS-CoV-2, as detected by RT-qPCR, immunohistochemistry, and in situ hybridisation in the nasal cavity of intranasally SARS-CoV-2-inoculated fruit bats 86 (Table 1 and Table S1 ).

Several studies showed evidence based on metagenomic sequencing analysis that pangolins (Manis javanica), a group of endangered mammals, may harbour the ancestral beta-CoVs, which is the second closest relative SARS-CoV-2 virus. 29 

There have been several reports of human-to-feline transmission of SARS-CoV-2 (Table 1 and Table S1 ). Cats from Belgium and Hong

Kong tested SARS-CoV-2-positive. 87 Cats were shown to be susceptible to SARS-CoV-2 and that they may transmit the virus to other cats in close-contact. 88 (Table 1 and Table S1 ).

To date, there has been one report of mink infection with SARS-CoV-2. 13 including interstitial pneumonia. 13 Investigations later revealed that workers at the farm had previously tested positive for Covid-19, suggestive of human-to-animal transmission ( Table 1 and Table S1 ).

It has been shown that all NHPs are susceptible to previous SARS-CoV infection where symptoms of fever, diarrhoea and pneumonitis were reported. 91, 92 Recent studies have shown that rhesus macaques are susceptible to SARS-CoV-2 infection. The virus was found to cause mild pneumonia similar to that in humans. 30 Additionally, infected rhesus macaques developed NAbs that may protect them from subsequent infections. 30 Other NHPs, such as cynomolgus macaques and common marmosets were shown to be susceptible to SARS-CoV-2 infection 29 (Table 1 and   Table S1 ). However, comparing the susceptibility of rhesus macaques to cynomolgus macaques and common marmosets, the former showed higher susceptibility to SARS-CoV-2 infection. It is worth mentioning that viral replication of nasopharyngeal swabs, anal swabs and lung in old monkeys was more active than that in young monkeys for 14 days after SARS-CoV-2 challenge. 31 In addition, old monkeys exhibited diffuse severe interstitial pneumonia compared to young monkeys. Interestingly, a notably higher percentage of lymphocytes was observed in younger monkeys F I G U R E 4 Animal host classification according to susceptibility. NHPs, hamsters, transgenic mice, felines, ferrets, minks, pangolins, and rabbits have high susceptibility, dogs have low susceptibility, while pigs, poultry, and tree shrews have no susceptibility to SARS-CoV-2 infection; SARS-CoV-2, severe acute respiratory syndrome coronavirus-2 YOUNES ET AL.

-7 of 13 compared to older monkeys, but the decreased counts of lymphocytes were found in both age groups. 31

Several studies have shown that hamsters are susceptible to SARS-CoV-2 infection (Table 1 and Table S1 ). Golden Syrian hamsters infected with SARS-CoV-2 developed clinical signs, such as lethargy, ruffled fur, hunched back, abnormal breathing and weight loss. [21] [22] [23] In addition, viral transmission to naive hamsters through direct contact was described. 22 Of particular interest is the fact that infection with SARS-CoV-2 in hamsters reflects some of the 

A recent study showed that SARS-CoV-2 can infect rabbits, and thus they may serve as potential sources of animal to human transmission (Table 1 and Table S1 ). 45 Nevertheless, whether or not rabbits are naturally susceptible to the virus remains under investigation.

Dogs Under natural conditions, there have been few reports of dogs that have tested SARS-CoV-2-positive, of which none reported that dogs could pose as a source of infection for humans (Table 1 and 11 and thus, failed to show potential for serving as animal models of SARS-CoV-2 infection (Table 1 and Table S1 ).

A recent study was conducted to investigate whether pigs are susceptible to SARS-CoV-2 or not (Table 1 and Table S1 ). Swabs were found to be free from viral RNA, in addition, no viral RNA was detected in any of the naïve animals in contact, indicating that pigs (Table 1 and Table S1 ). Viral RNA was not detected in swabs taken from SARS-CoV-2-inoculated chickens and ducks. In addition, viral RNA was not detected in any of the naïve animals that were in close contact, indicating no animal-to-animal transmission.

Furthermore, the inoculated chickens and ducks were found to be seronegative when tested by ELISA. 11

Experimental infection of tree shrews with SARS-CoV-2 has been described 63 (Table 1 and Table S1 ). No clinical signs were observed in SARS-CoV-2-inoculated tree shrews except high body temperature, 63 and thus, may not be a suitable animal for Covid-19 research.

Other animals are still under investigation whether or not they are susceptible to SARS-CoV-2 infection and if they can be useful as models. In Silico Analysis revealed that wild felidae, goats, spotted hyenas and civets may be SARS-CoV-2-susceptible and could potentially act as intermediate hosts to transmit the virus from bats to humans. 95 These findings highlight the usefulness of these animals to be used as experimental animal models for studying SARS-CoV-2 infection directly without the need for transgenic operation. 95 It is noteworthy to mention that rodents, birds, and reptiles are unlikely to be susceptible to SARS-CoV-2, 95 however, further investigation is needed.

Not every susceptible animal can serve as a good model for testing vaccine and therapeutic candidates. A good animal model is defined by its ability to reproduce relevant human physiology to be used for investigating the effectiveness of potential therapeutic agents and pharmacological drugs. Thus, the identification of reliable and 

Mouse models are known to be convenient models to study a disease because they are cheap, available and easy to manipulate. However, these models are challenging to study SARS-CoV-2 due to differences in the usage pattern of angiotensin-converting enzyme 2 (ACE2) receptor compared to human, 96 

Ferrets have been widely used to study viral respiratory diseases in humans and remain one of the best candidates as an animal model for respiratory tract infections as they display most of the human-like symptoms. 71 Unlike mice, ferrets can be infected with the virus without prior transgenic adaptation. Ferrets were used as animal models for evaluating the effectiveness of antiviral drugs against influenza, 100 SARS-CoV 101 and Ebola. 102 Thus, researchers believe that ferrets may help in the race for finding the best therapeutic drugs and vaccines against SARS-CoV-2. A recent study that investigated the efficacy of different antivirals agents using infected ferrets, has revealed a reduction in the overall clinical scores following treatment with three antiviral agents; lopinavir-ritonavir, hydroxychloroquine sulphate, and emtricitabine-tenofovir 18 (Table S2 ).

The (Table S2 ).

NHPs are considered as one of the best animal models to investigate potential antiviral drugs, therapeutic agents, and to gain a better understanding of the aspects related to pathology in different infectious diseases. 103 

Other animals that have been used for vaccine studies in Covid-19

research include pigs and rabbits (Table S2) . However, there is a lack YOUNES ET AL. of studies on these animals, and thus, further investigation on the usefulness of these animals as models is needed. hamsters and ferrets may serve as a useful model for studying the virus transmission and the efficacy of antiviral drugs to limit the spread of the infection. Most importantly, the NHPs were demonstrated to be the most relevant animal model to assess the antiviral agents and vaccine effectiveness before rapid deployment to clinical trials on humans. Although there are more than 180 vaccine candidates and more than 23 well-known pharmaceutical companies that are trying to produce an effective vaccine against SARS-CoV-2, until now, no vaccines were finally approved for human use. However, the current literature data so far proposed that safe vaccines could be available within the coming few months. For more information about vaccine development, the readers are advised to refer back to this comprehensive review and website. 106, 107 It is clear now that among all virus proteins, the most antigenic target for successful active or passive vaccination against all coronavirus, including SARS-CoV-2, is the S1 subunit of the spike S proteins; more specifically, the RBDs of the S1 subunit. That is, if a vaccinated host produces NAbs to the RBD, it will block virus binding and, consequently, viral replication. In fact, it was shown that passive vaccination with a cocktail of humanized monoclonal antibodies targeting the RBD has shown effectiveness in the treatment of Covid-19 patients. 108 The RBD viral antigen could be injected in a form of self-replicating mRNA or a recombinant protein. Different delivery systems are currently being used in clinical trials for delivering the virus RNA or the recombinant protein such as the lipid nanoparticles or the non-pathogenic adenovirus associated vector. Moreover, other companies are also trying to produce live attenuated (a genetically weakened version of the virus) or chemically inactivated whole virus vaccine. 106 Finally, our systematic search revealed that viral shedding from pets is not sufficient to infect other members of the family or other animals. However, susceptible animals could serve as reservoirs of the virus, necessitating careful ongoing animal management and surveillance.

Open access funding provided by the Qatar National Library. This The statements made herein are solely the responsibility of the authors.

WHO Coronavirus disease (COVID-19) [Online; WHO

Human coronavirus-229E, -OC43, -NL63, and -HKU1

Viral, host and environmental factors that favor anthropozoonotic spillover of coronaviruses: an opinionated review, focusing on SARS-CoV, MERS-CoV and SARS-CoV-2. Sci Total Environ

Novel human coronavirus (SARS-CoV-2): a lesson from animal coronaviruses

SARS-CoV-2 infection boosts MX1 antiviral effector in COVID-19 patients. iScience

The incidence of the novel coronavirus SARS-CoV-2 among asymptomatic patients: a systematic review

Challenges in laboratory diagnosis of the novel coronavirus SARS-CoV-2

Generation of a broadly useful model for COVID-19 pathogenesis, vaccination, and treatment

Rheumatologists' perspective on coronavirus disease 19 (COVID-19) and potential therapeutic targets

Preferred reporting Items for systematic reviews and meta-analyses: the PRISMA statement

Susceptibility of ferrets, cats, dogs, and other domesticated animals to SARS-coronavirus 2

SARS-CoV-2 neutralizing serum antibodies in cats: a serological investigation

SARS-CoV-2 infection in farmed minks, the Netherlands

The pathogenicity of SARS-CoV-2 in hACE2 transgenic mice

First detection and genome sequencing of SARS-CoV-2 in an infected cat in France

Absence of SARS-CoV-2 infection in cats and dogs in close contact with a cluster of COVID-19 patients in a veterinary campus

Experimental transmission studies of SARS-CoV-2 in fruit bats, ferrets, pigs and chickens

Antiviral efficacies of FDA-approved drugs against SARS-CoV-2 infection in ferrets

SARS-CoV-2 is transmitted via contact and via the air between ferrets

Imbalanced host response to SARS-CoV-2 drives development of COVID-19

Syrian hamsters as a small animal model for SARS-CoV-2 infection and countermeasure development

Pathogenesis and transmission of SARS-CoV-2 in golden hamsters

Simulation of the clinical and pathological manifestations of coronavirus Disease 2019 (COVID-19) in a golden Syrian hamster model: implications for disease pathogenesis and transmissibility. Clin Inf Dis

Age-dependent progression of SARS-CoV-2 infection in Syrian hamsters

Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model

Hydroxychloroquine proves ineffective in hamsters and macaques infected with SARS-CoV-2. bioRxiv

STAT2 signaling as double-edged sword restricting viral dissemination but driving severe pneumonia in SARS-CoV-2 infected hamsters

High potency of a bivalent human VH domain in SARS-CoV-2 animal models

Comparison of SARS-CoV-2 infections among 3 species of non-human primates

Reinfection could not occur in SARS-CoV-2 infected rhesus macaques

Age-related rhesus macaque models of COVID-19

Single-dose replicating RNA vaccine induces neutralizing antibodies against SARS-CoV-2 in nonhuman primates

ChAdOx1 nCoV-19 vaccination prevents SARS-CoV-2 pneumonia in rhesus macaques

Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2

Development of an inactivated vaccine candidate, BBIBP-CorV, with potent protection against SARS-CoV-2

DNA vaccine protection against SARS-CoV-2 in rhesus macaques

SARS-CoV-2 infection protects against rechallenge in rhesus macaques

Characteristic and quantifiable COVID-19-like abnormalities in CT-and PET/CT-imaged lungs of SARS-CoV-2-infected crab-eating macaques (Macaca fascicularis)

Transmission of SARS-CoV-2 in domestic cats

Respiratory disease and virus shedding in rhesus macaques inoculated with SARS-CoV-2. bioRxiv

Establishment of an African green monkey model for COVID-19

Rapid development of an inactivated vaccine candidate for SARS-CoV-2

Ocular conjunctival inoculation of SARS-CoV-2 can cause mild COVID-19 in rhesus macaques

Vascular disease and thrombosis in SARS-CoV-2-infected Rhesus Macaques

Susceptibility of rabbits to SARS-CoV-2. bioRxiv

Antibody signature induced by SARS-CoV-2 spike protein immunogens in rabbits

Pathogenesis of sars-cov-2 in transgenic mice expressing human angiotensin-converting enzyme 2

A mouse-adapted SARS-CoV-2 model for the evaluation of COVID-19 medical countermeasures

A mouse model of SARS-CoV-2 infection and pathogenesis

Mouse model of SARS-CoV-2 reveals inflammatory role of type I interferon signaling

Remdesivir potently inhibits SARS-CoV-2 in human lung cells and chimeric SARS-CoV expressing the SARS-CoV-2 RNA polymerase in mice

An orally bioavailable broadspectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice

A noncompeting pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2

Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion

Key residues of the receptor binding motif in the spike protein of SARS-CoV-2 that interact with ACE2 and neutralizing antibodies

Potently neutralizing human antibodies that block SARS-CoV-2 receptor binding and protect animals

Potent neutralization of SARS-CoV-2 in vitro and in an animal model by a human monoclonal antibody

Rapid adaptation of SARS-CoV-2 in BALB/c mice: novel mouse model for vaccine efficacy

Cross-reactive antibody response between SARS-CoV-2 and SARS-CoV infections

A mouse-adapted SARS-CoV-2 induces acute lung injury and mortality in standard laboratory mice

Characterization of local SARS-CoV-2 isolates and pathogenicity in IFNARÀ /-mice

Infection of dogs with SARS-CoV-2

Susceptibility of tree shrew to SARS-CoV-2 infection

Batborne virus diversity, spillover and emergence

Identifying SARS-CoV-2-related coronaviruses in Malayan pangolins

Analysis of possible intermediate hosts of the new coronavirus SARS-CoV-2

Cross-species transmission of the newly identified coronavirus 2019-nCoV

The potential intermediate hosts for SARS-CoV-2

Probable pangolin origin of SARS-CoV-2 associated with the COVID-19 outbreak

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

A new coronavirus associated with human respiratory disease in China

The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health-the latest 2019 novel coronavirus outbreak in Wuhan, China

Composition and divergence of coronavirus spike proteins and host ACE2 receptors predict potential intermediate hosts of SARS-CoV-2

Severe acute respiratory syndrome coronavirus 2-specific antibody responses in coronavirus disease patients

Coronaviruses: A paradigm of new emerging zoonotic diseases

Origin and evolution of pathogenic coronaviruses

A pneumonia outbreak associated with a new coronavirus of probable bat origin

Initial cluster of novel coronavirus (2019-nCoV) infections in Wuhan, China is consistent with substantial human-to-human transmission

The proximal origin of SARS-CoV-2

Review of bats and SARS

Bat-to-human: spike features determining 'host jump' of coronaviruses SARS-CoV, MERS-CoV, and beyond

Bat coronaviruses in China

Clinical diagnosis of 8274 samples with 2019-novel coronavirus in Wuhan. medRxiv

Emerging novel coronavirus (2019-nCoV)-current scenario, evolutionary perspective based on genome analysis and recent developments

History is repeating itself: probable zoonotic spillover as the cause of the 2019 novel Coronavirus Epidemic

SARS-CoV-2 in fruit bats, ferrets, pigs, and chickens: an experimental transmission study

CoV-2 in animals American Veterinary Medical Association

China set to clamp down permanently on wildlife trade in wake of coronavirus

Coronavirus can infect cats -dogs, not so much

USDA Statement on the Confirmation of COVID-19 in a Tiger in New York

Animal models for SARS and MERS coronaviruses

Development of animal models against emerging coronaviruses: from SARS to MERS coronavirus

Infection and rapid transmission of SARS-CoV-2 in ferrets

Susceptibility of pigs and chickens to SARS coronavirus

In silico analysis of intermediate hosts and susceptible animals of SARS-CoV-2. ChemRxiv

COVID-19: animals, veterinary and zoonotic links

Transmission of SARS-CoV-2 via close contact and respiratory droplets among hACE2 mice

A SARS-CoV-2 infection model in mice demonstrates protection by neutralizing antibodies

Mouse model of SARS-CoV-2 reveals inflammatory role of type I interferon signaling

Using the ferret as an animal model for investigating influenza antiviral effectiveness

Animal models and vaccines for SARS-CoV infection

Comparative transcriptomics in Ebola Makona-infected ferrets, nonhuman primates, and humans

Non-human primates as a model for aging

Comparative pathogenesis of COVID-19, MERS, and SARS in a nonhuman primate model

Estimating the asymptomatic proportion of coronavirus disease 2019 (COVID-19) cases on board the Diamond Princess cruise ship

SARS-CoV-2 vaccines in development

These 23 companies are working on coronavirus treatments or vaccines -here's where things stand

COVID-19 antibodies on trial

A mouse-adapted model of SARS-CoV-2 to test COVID-19 countermeasures

Severe acute respiratory syndrome coronavirus-2 natural animal reservoirs and experimental models: systematic review

The authors declare that they have no competing interests.

Conceptualization, Gheyath K. Nasrallah; data curation, Salma